Every day thousands of investors flock to the markets to discover the next big thing from among penny stocks. The following for these stocks is substantial since it is possible for an investor to pick up a large number of shares for a relatively low outlay. If the stock moves in the right direction then the investor could end up making substantial gains.

This article is going to provide you with a look into four penny stocks that you could consider tracking at this point in time. Although many of the penny stocks in the market have suffered in recent times due to the overall weakness in the markets, here are a few stocks that have managed to hold on to buy ratings overall.

Nano Dimension (NASDAQ:NNDM) – The first one that you could consider tracking this week is the Nano Dimension stock. The company is involved in the additive manufacturing space. While it is true that analysts believe that there is considerable upside in the stock at this point in time, there is something else that investors need to worry about and that is growth. The weak growth fundamentals of the stock are weighing on the stock at this point in time and it remains to be seen if it can manage to make a comeback any time soon.

HyreCar (NASDAQ:HYRE) – The next one to make it to this list is HyreCar. It remains one of the more interesting companies in its sector and investors could do well to keep an eye on its progress. While it is true that HyreCar could not be considered a hugely high-growth company, its operations are moving in the right direction and that could be a reason to keep track of it.

MannKind (NASDAQ:MNKD) – Pharmaceutical companies are almost always worth looking into and in penny stock land, it may be a good move to track MannKind. In this regard, it should be noted that MannKind has continued to make losses but that has not deterred analysts from continuing to put a buy rating on the stock. It might be a good time to start tracking the stock.

Agenus (NASDAQ:AGEN) – Last but certainly not least, it is the Agenus stock that may be worth tracking from among penny stocks. The company boasts of a considerably strong pharmaceutical partners’ network. At the same time, it is working on unique cancer treatment. That makes it a company that may be of interest to investors.

By Ruchika Gupta

I am Ruchika Gupta, a post-graduate woman. Having completed my Masters - in English. I like to write and thus have worked as a content writer for over nine years. I have gained much insight into the financial sector, having written plenty about it. Currently, I have been following up and writing on the biotech industry, which has given me handsome knowledge of the same.

Leave a Reply

Your email address will not be published.